Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer.

Lund RR, Leth-Larsen R, Caterino TD, Terp MG, Nissen J, Lænkholm AV, Jensen ON, Ditzel HJ.

Mol Cell Proteomics. 2015 Nov;14(11):2988-99. doi: 10.1074/mcp.M115.050385. Epub 2015 Sep 8.

2.

miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations.

Thomsen KG, Terp MG, Lund RR, Søkilde R, Elias D, Bak M, Litman T, Beck HC, Lyng MB, Ditzel HJ.

Oncotarget. 2015 Oct 6;6(30):29224-39. doi: 10.18632/oncotarget.4942.

3.

Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.

Terp MG, Olesen KA, Arnspang EC, Lund RR, Lagerholm BC, Ditzel HJ, Leth-Larsen R.

J Immunol. 2013 Oct 15;191(8):4165-73. doi: 10.4049/jimmunol.1301274. Epub 2013 Sep 16.

4.

Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics.

Terp MG, Lund RR, Jensen ON, Leth-Larsen R, Ditzel HJ.

Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):265-73.

PMID:
22990106
5.

Quantitative proteomics of primary tumors with varying metastatic capabilities using stable isotope-labeled proteins of multiple histogenic origins.

Lund RR, Terp MG, Laenkholm AV, Jensen ON, Leth-Larsen R, Ditzel HJ.

Proteomics. 2012 Jul;12(13):2139-48. doi: 10.1002/pmic.201100490. Epub 2012 Jun 18.

PMID:
22623409
6.

Plasma membrane proteomics and its application in clinical cancer biomarker discovery.

Leth-Larsen R, Lund RR, Ditzel HJ.

Mol Cell Proteomics. 2010 Jul;9(7):1369-82. doi: 10.1074/mcp.R900006-MCP200. Epub 2010 Apr 8. Review.

7.

Percutaneous fetal ventriculography. A new technic and case report.

Robertson CH, Lund RR, Soroosh F, Cheatham GR Jr.

Obstet Gynecol. 1969 Dec;34(6):841-6. No abstract available.

PMID:
5308428
8.

STRONTIUM 85 PHOTOSCANNING IN PAGET'S DISEASE; WITH COMMENTS ON SEVERAL OTHER SKELETAL PROBLEMS.

KLEIN EW, LUND RR.

Am J Roentgenol Radium Ther Nucl Med. 1964 Jul;92:195-201. No abstract available.

PMID:
14176032
9.

Vena cavagraphy in the management of malignancy.

SAMMONS BP, LUND RR, PISCHNOTTE WO.

Am J Roentgenol Radium Ther Nucl Med. 1961 Oct;86:718-29. No abstract available.

PMID:
13745929
10.

Inferior vena cavography in preoperative localization of pheochromocytoma.

LUND RR, GARCIA NA 3rd, LE BLANC GA, GARTENLAUB C, RICHARDSON JF.

J Urol. 1960 May;83:768-73. No abstract available.

PMID:
14418899
11.

Contrast visualization of the venae cavae in management of lymphoma.

SAMMONS BP, LUND RR, PISCHNOTTE WO, GARTENLAUB C.

J Am Med Assoc. 1959 Feb 14;169(7):704-6. No abstract available.

PMID:
13620526
12.

Simplified phlebography of the inferior vena cava in urologic diagnosis.

SAMMONS BP, LUND RR, PISCHNOTTE WO, RICHARDSON JF.

Radiology. 1959 Feb;72(2):222-6. No abstract available.

PMID:
13634380
13.

Simultaneous occurrence of subcostosternal (Morgagni) hernia and hiatus hernia; report of a case.

LUND RR, CRISLER EC, SAMMONS BP, GARTENLAUB C.

Radiology. 1958 Apr;70(4):561-3. No abstract available.

PMID:
13542805
14.

The role of the urine in vesical neoplasm. I. Experimental confirmation of the urogenous theory of pathogenesis.

McDONALD DF, LUND RR.

J Urol. 1954 May;71(5):560-70. No abstract available.

PMID:
13152884
15.

The role of the urine in vesical carcinoma. I. Confirmation of the urogenous theory of pathogenesis.

MCDONALD DF, LUND RR.

Trans West Sect Am Urol Assoc. 1952;19:162; discussion 170-5. No abstract available.

PMID:
13064725

Supplemental Content

Support Center